RxDoctor Payments Data

Norris Royston, MD

Family Medicine · Marshall, VANPI 1124055066

Payments from drug & device makers

$446in general payments, 2019–2025

Across 15 payments — averaging $29.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$123
  • Esperion Therapeutics, Inc.$112
  • Johnson & Johnson$80
  • E.r. Squibb & Sons, L.L.C.$33
  • Pfizer$33
  • AbbVie$20
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$446100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$446 in reported general payments places this provider in the 55th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$148,228
Medicare patients
355
Services billed
1,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$81,438
OzempicSemaglutide49$66,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,383
RybelsusSemaglutide24$21,748
JanumetSitagliptin Phos/Metformin Hcl11$5,395
BystolicNebivolol Hcl13$5,272
SynthroidLevothyroxine Sodium71$4,940
Rosuvastatin Calcium315$4,775
SymbicortBudesonide/Formoterol Fumarate16$3,582
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$3,224
Potassium Chloride111$2,602
DilantinPhenytoin Sodium Extended22$2,170
ValacyclovirValacyclovir Hcl14$1,956
Levothyroxine Sodium171$1,676
Ranolazine ErRanolazine12$1,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$123$88,72073 claims
PfizerEliquis, Dilantin, Paxlovid$33$85,038130 claims
MerckJanumet$16$5,39511 claims
AbbVieSynthroid$20$4,94071 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Marshall

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →